KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Gains from Investment Securities (2019 - 2025)

Inovio Pharmaceuticals' Gains from Investment Securities history spans 13 years, with the latest figure at -$890888.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 228.64% year-over-year to -$890888.0; the TTM value through Sep 2025 reached -$2.8 million, down 172.53%, while the annual FY2024 figure was -$1.9 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$890888.0 at Inovio Pharmaceuticals, down from $3.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.9 million in Q2 2021 and bottomed at -$4.6 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is -$334297.0 (2023), against an average of -$258339.7.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 104695.5% in 2021 before it crashed 437.19% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$4.6 million in 2021, then soared by 104.13% to $190839.0 in 2022, then surged by 1919.34% to $3.9 million in 2023, then plummeted by 149.44% to -$1.9 million in 2024, then soared by 53.24% to -$890888.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Gains from Investment Securities are -$890888.0 (Q3 2025), $3.7 million (Q2 2025), and -$3.7 million (Q1 2025).